Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Lee, 2014, Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks follow-up, PLoS One, 9, e97482, 10.1371/journal.pone.0097482 Eron, 2013, Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials, Lancet Infect Dis, 13, 587, 10.1016/S1473-3099(13)70093-8 Elion, 2013, A randomized phase 3 study comparing once-daily elvitegravir to twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results, J Acquir Immune Defic Syndr, 63, 494, 10.1097/QAI.0b013e318298469c Zolopa, 2010, Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial, J Infect Dis, 201, 814, 10.1086/650698 Schrijvers, 2012, Quad's in it for antiretroviral therapy?, Lancet, 379, 2403, 10.1016/S0140-6736(12)61029-0 Cahn, 2013, Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study, Lancet, 382, 700, 10.1016/S0140-6736(13)61221-0 Capetti, 2014, Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E study, Int J Antimicrob Agents, 43, 189, 10.1016/j.ijantimicag.2013.10.013 Elion, 2013, A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results, J Acquir Immune Defic Syndr, 63, 494, 10.1097/QAI.0b013e318298469c Eron, 2013, Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials, Lancet Infect Dis, 13, 587, 10.1016/S1473-3099(13)70093-8 Molina, 2012, Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study, Lancet Infect Dis, 12, 27, 10.1016/S1473-3099(11)70249-3 Kulkarni, 2014, Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients, HIV Clin Trials, 15, 218, 10.1310/hct1504-218 Lennox, 2009, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, Lancet, 374, 796, 10.1016/S0140-6736(09)60918-1 Raffi, 2013, Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 13, 927, 10.1016/S1473-3099(13)70257-3 Ford, 2013, Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744, Antimicrob Agents Chemother, 57, 5472, 10.1128/AAC.01235-13 Spreen, 2013, Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor, HIV Clin Trials, 14, 192, 10.1310/hct1405-192 Nelson, 2013, Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies, HIV Clin Trials, 14, 81, 10.1310/hct1403-81 Spreen, 2013, Long-acting injectable antiretrovirals for HIV treatment and prevention, Curr Opin HIV AIDS, 8, 565, 10.1097/COH.0000000000000002 Spreen, 2014, GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects, J Acquir Immune Defic Syndr, 67, 481, 10.1097/QAI.0000000000000301 Jackson, 2014, A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis, Clin Pharmacol Ther, 96, 314, 10.1038/clpt.2014.118 Johnson, 2013, Update of the drug resistant mutations in HIV-1: March 2013, Top Antivir Med, 21, 6 Stellbrink, 2013, Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study, AIDS, 27, 1771, 10.1097/QAD.0b013e3283612419 Walmsley, 2013, Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection, N Engl J Med, 369, 1807, 10.1056/NEJMoa1215541 Dudas, 2015, Resistance mutations observed in a study subject on oral two-drug maintenance therapy with 10 mg cabotegravir + 25 mg rilpivirine, Glob Antivir J, 11 Gallego, 2004, Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz, Clin Infect Dis, 38, 430, 10.1086/380791